Clinical bottom line
Chronic rhinosinusitis with nasal polyps (CRSwNP) remains a challenging condition with significant morbidity, particularly in adults with severe or refractory disease. Emerging approaches emphasize the integration of biologic therapies targeting type 2 inflammation, such as anti-IL-5 agents like mepolizumab, alongside optimized surgical and medical management. Evidence supports biologics as effective adjuncts to reduce polyp burden, improve symptoms, and decrease the need for systemic corticosteroids. However, patient selection based on endotype and biomarker profiles is critical to maximize benefit. Multidisciplinary care and individualized treatment plans are essential for optimal outcomes (Neposlan et al., 2023; Bachert et al., 2022).
What the evidence shows
Neposlan et al. (2023) review the role of mepolizumab, an anti-IL-5 monoclonal antibody, in adult CRSwNP, demonstrating significant reductions in nasal polyp size, symptom scores, and corticosteroid use in randomized controlled trials. These benefits are particularly notable in patients with elevated eosinophilic inflammation.
Bachert et al. (2022) provide a comprehensive overview of biologics in CRSwNP, highlighting several agents targeting IL-4, IL-5, and IgE pathways. Their analysis underscores the importance of biomarker-driven therapy to tailor treatment and improve efficacy.
Marioni et al. (2018) assess CRSwNP in the elderly, noting that age-related immune changes may influence disease presentation and response to therapy, necessitating careful evaluation in this population.
Brescia et al. (2020) identify blood eosinophil and basophil levels as prognostic markers in allergic fungal rhinosinusitis, a CRSwNP subtype, suggesting that peripheral biomarkers can guide management strategies.
Park et al. (2014) discuss the pathophysiology of nasal polyps and chronic rhinosinusitis, emphasizing the role of type 2 inflammation and the rationale for targeted biologic interventions.
Erdem Eralp et al. (2026) provide insights into sinonasal disease in primary ciliary dyskinesia, a condition often complicated by nasal polyps, highlighting the need for tailored approaches in complex cases.
Caveats and uncertainty
Long-term safety and durability of biologic therapies require further study.
High cost and access limitations may restrict widespread use of biologics.
Optimal biomarkers for patient selection and treatment monitoring are still being refined.
Surgical intervention remains necessary for many patients, and timing relative to biologic therapy is not fully standardized.
Heterogeneity in CRSwNP endotypes complicates uniform treatment algorithms.
How this may change practice
Clinicians should consider biologic therapies, particularly anti-IL-5 agents like mepolizumab, for patients with severe or refractory CRSwNP characterized by eosinophilic inflammation.
Routine assessment of blood eosinophils and other biomarkers can aid in identifying candidates for targeted therapy.
Multidisciplinary collaboration between otolaryngologists, allergists, and immunologists is key to comprehensive care.
Integration of biologics may reduce reliance on systemic corticosteroids and improve quality of life.
Ongoing research and guideline updates will inform optimal sequencing and combination of medical and surgical treatments.